Oral squamous cell carcinoma (OSCC) is the most common oral malignancy. However, combinations of more aggressive treatments have been unable to substantially improve the 5-year survival rate, due to a 10-30% locoregional recurrence rate. Conventional approaches such as physical examination, magnetic resonance imaging (MRI) and computed tomography (CT) are generally presumed insufficient for detecting residual or recurrent tumors during follow-up. Posttreatment prediction of tumor recurrence remains a diagnostic challenge. This article reviews the utilization of various non-invasive imaging modalities, such as 18 F-fluorodeoxyglucose-positron emission tomography (PET), PET/ CT, MRI, dynamic contrast-enhanced-MRI, diffusion-weighted MRI, CT, perfusion-CT and ultrasonography in addition to physical examination for earlier prediction of tumor recurrence in patients with OSCC during follow-up. A need for high-level scientific evidence remains, to guide us to the optimal radiological strategies for earlier prediction of tumor recurrence in OSCC. Further investigation is thus needed to standardize these methods for predicting tumor recurrence.
Introduction
Head and neck carcinoma is the sixth most common malignancy reported worldwide, with oral squamous cell carcinoma (OSCC) predominating in this region (1) . Despite aggressive combinations of treatments such as surgery, radiotherapy and chemotherapy, 5-year survival rates of head and neck squamous cell carcinoma (HNSCC) HNSCC patients have improved only moderately, partly due to the relatively high rate of local recurrence. Even when the surgical margins are diagnosed as tumor-free on histopathology, the local recurrence rate is still 10-30% (2) . In cannot assess tumor response to therapy, which is a crucial factor in predicting recurrence (5) . Endoscopic evaluation is nevertheless minimally invasive; it may still cause patient discomfort. The timeline of usual follow-up for recurrence prediction is 5 years after treatment but, it is a long-term process that may deteriorate patient survival (6) .
Conventional approaches are generally accepted as insufficient surveillance methods for predicting tumor recurrence (7) . Clearly, there is a need for early, better and more sensitive modalities to achieve the earlier prediction of disease recurrence in OSCC. Posttreatment surveillance of OSCC remains a diagnostic challenge (8) . Various non-invasive imaging modalities such as 18 PET/CT is another highly advanced approach for recurrence prediction in HNSCC, offering 100% sensitivity and 85% specificity. This modality may predict recurrence at 8-12 weeks after initial treatment (3) . In a meta-analysis, PET offered 94% overall pooled sensitivity for the detection of residual tumors, recurrence and distant metastases, with a 95% negative predictive value for the primary site as the initial evaluation of CRT response (9) . Frequent use of US followed by physical examination provides good sensitivity and specificity for predicting recurrence in comparison to physical examination alone during the first year of follow-up (10) . Conventional MRI and CT have good sensitivity, but lower specificity as compare to other non-invasive imaging modalities. Moreover, DW-MRI, DCE-MRI and PCT have also been employed for predicting recurrence and evaluating treatment response in HNSCC with much improved sensitivity and specificity. DWI with the apparent diffusion coefficient (ADC) is very helpful in detecting subcentimetric metastases. DCE-MRI provides tissue perfusion or permeability, whereas PCT reveals parameters of tumor physiology. All these parameters are very helpful in predicting residual or recurrent disease, along with treatment response. Despite all these findings, such non-invasive imaging modalities need further standardization before entering use in the routine clinical setting. This article aims to review the purpose of all the above imaging modalities for predicting tumor recurrence in OSCC.
Materials and Methods
Database searches using PubMed, Google Scholar and This modality can detect tumor recurrences before any clinical appearance at regular follow-up (8) . However, some non-specific mucosal changes that supervene after CRT may be associated with false-negative findings when FDG-PET is performed within 8-10 weeks after CRT(9). FDG-PET within 2 months after treatment is good to evaluate CRT response rather than search for recurrence.
FDG-PET at ≥ 12 weeks after CRT may provide a higher negative predictive value (NPV) because of reconstruction in cases with negative scans (11) . FDG-PET appears useful in the surveillance of OSCC after surgical salvage therapy.
Among patients followed for a median of 33.6 months after second-line therapy, PET has an overall sensitivity of 85% (92% for recurrence or second primaries, 88% for lymph node failure and 73% for distant metastases) (12) .
Performance of FDG-PET for OSCC seems promising for the detection of tumor recurrence, reportedly offering 100% sensitivity, 43% specificity, a positive predictive value (PPV) of 51% and a NPV of 100%, when performed at 3-6 months after treatment. One limitation of FDG-PET is the low specificity and PPV. A high false-positive risk is more easily accepted as long as sensitivity approaches 100% and false-positive results do not increase the risk of patient morbidity. Many false-positive scans can be related to distinct pathological lesions other than SCC and in fact are recognized by clinical assessment or other imaging techniques. Therefore, systematic 18 F-FDG PET performed once at 3-6 months after treatment is recommended for earlier prediction of recurrence. High focal 18 F-FDG uptake without a correlating anatomical substrate raises a diagnostic dilemma (8) . Sometimes SCC of the oral tongue (SCCOT) shows only faint FDG uptake that is measured as a physiological uptake by FDG-PET. To avoid misinterpretation of tongue carcinoma, physical examination should also be performed (13) . The drawback of FDG-PET is the lack of anatomical detail, which is responsible for the low specificity and PPV. The higher chance of false-positive results may be related to other pathological lesions rather than SCC. FDG uptake by SCC or other lesions cannot be discriminated by nuclear physicians (8) . Use of a dual-imaging modality, such as 18 Table 2 . Follow-up schema for CT (Rivelli et al., 2011) from a negative examination. (31) . PCT in clinical routine use is very helpful in discriminating recurrent disease from (36) . We may therefore predict tumor recurrence and evaluate PFS and therapeutic response in OSCC by considering PCT-revealed parameters.
US
US is able to efficiently explore subclinical regional recurrences with 81% sensitivity, 87% specificity, 83% PPV and 85% NPV at a mean follow-up of 14 months after initial treatment. The overall accuracy for PET/CT and US was 84% in detecting subclinical regional recurrences. This modality is less time-consuming and inexpensive in comparison to above illustrated modalities with no exposure of patients to radiation (37) . Moreover, B-mode US also appears very sensitive for discriminating between postoperative edema and early tumor recurrence in OSCC patients.
B-mode US is also able in identifying malignancy in solid scarred neck tissues (38) . 
Conclusion
In conclusion, application and the roles of all these non-invasive imaging modalities in addition to physical examination seem highly efficient for the earlier detection of residual or recurrent tumor as well as tumor response during the follow-up of patients after curative treatment.
The available literature suggests that PET/CT represents the most sensitive and specific modality for earlier prediction of OSCC recurrence when performed 8-12 weeks after initial treatment. DW-MRI is able to probe the tissue microstructure and the addition of DW-MRI to DCE-MRI increases the accuracy of early tumor prediction during follow-up of patients with OSCC. PCT-divulged microcirculatory parameters also cannot be ignored, since these show direct relationships with tumor recurrence. The accuracy of US with physical examination in predicting subclinical regional recurrences is similar to that of PET/CT and could be regarded as complementary to PET/CT. However, high-level scientific evidence remains lacking, and is needed to determine optimal radiological strategies for earlier Table 3 . Summary of all imaging modalities with sensitivity, specificity, advantages and limitations in earlier prediction of residual or recurrent tumor in OSCC.
